Neowise Biotechnology
PrivateLast Round
Series B
Jan 26, 2026
Total Funding Raised
$72.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neowise Biotechnology operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series B round in January 2026.
Neowise Biotechnology is a biotechnology company that develops TCR-T cell therapies for solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neowise Biotechnology Comparables
Compare Neowise Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anocca | 86% | |
| T-Knife | 85% | |
| Beijing CorreGene Biotechnology Co., Ltd. | 85% |
For institutional investors. Book with your work email.
Neowise Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 26, 2026 | ||||
| Series A Extension | Mar 15, 2023 | ||||
| Series A | Oct 14, 2021 | ||||
| Angel | Oct 1, 2020 |
For institutional investors. Book with your work email.
Neowise Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriza Holdings | Series B |
| TF Capital | Series A |
| 健壹资本 | Series A |
| Baidu Ventures | Angel |
| Suzhou Angel Investment Guidance Fund | Series B |
| Marathon Venture Partners | Series A Extension |
| Delian Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 26, 2026
$28M round led by Apricot Capital
- Mar 15, 2023
$29M round with participation from Marathon Venture Partners and Oriza Seed.
For institutional investors. Book with your work email.
Neowise Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neowise Biotechnology's valuation, stock price, and market status.
Is Neowise Biotechnology a public or private company?
Neowise Biotechnology is a private company.
What is the current stock price of Neowise Biotechnology?
Neowise Biotechnology is a private company, so its shares have no public market price. Caplight tracks Neowise Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neowise Biotechnology worth (valuation)?
Valuation information for Neowise Biotechnology is not publicly available.
Can I buy Neowise Biotechnology stock?
Neowise Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neowise Biotechnology's last funding round?
Neowise Biotechnology's most recent funding round was Series B on January 26, 2026.
Who are the main investors in Neowise Biotechnology?
Key investors in Neowise Biotechnology include TF Capital, Apricot Capital.
Will Neowise Biotechnology IPO soon?
No public IPO plans have been announced for Neowise Biotechnology.
How can I track Neowise Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Neowise Biotechnology's shares on secondary markets.